iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
View Top Employees from iTeos TherapeuticsWebsite | http://www.iteostherapeutics.com |
Revenue | $15 million |
Funding | $360.6 million |
Employees | 173 (138 on RocketReach) |
Founded | 2011 |
Address | 139 Main Street, Cambridge, Massachusetts 02142, US |
Phone | (857) 204-4583 |
Technologies |
JavaScript,
HTML,
reCAPTCHA
+34 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Pharmaceuticals, Immunotherapy, Healthcare, Science and Engineering, Small molecule immunomodulators, Health Care, Drug discovery, Drug Manufacturing & Research, Medical |
Web Rank | 4 Million |
Keywords | Cancer Treatment |
Competitors | Altor Bioscience Corporation, IRX Therapeutics, Inc., Jounce Therapeutics, Inc., Lytix Biopharma, Qu Biologics Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 2834 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular iTeos Therapeutics employee's phone or email?
The iTeos Therapeutics annual revenue was $15 million in 2024.
138 people are employed at iTeos Therapeutics.
iTeos Therapeutics is based in Cambridge, Massachusetts.
The NAICS codes for iTeos Therapeutics are [32541, 32, 3254, 325].
The SIC codes for iTeos Therapeutics are [283, 28, 2834].